Raymond Q1 FY27: income up 13% YoY, net cash Rs 129 Cr

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

RAYMOND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.8%Reaction day

₹615.95

prior close

₹616.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+1.8% vs market

Industrial Products peers, median of 129sector+0.1%+1.6% vs sector

On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 1.6 pts more than its Industrial Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.0

10m

+0.3

15m

+1.1

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.8-0.1+1.8+0.1+1.6

Next day

+1.3-0.2+1.5+0.3+1.0

+0.7+0.1+0.6-0.3+1.1

+4.2+0.3+3.9-0.6+4.9

+3.2+0.4+2.8-1.2+4.4

+4.9+0.5+4.4-0.7+5.7

+2.6+0.3+2.3-1.0+3.6

15d

+2.3+1.9+0.5-1.3+3.7

+38.0+2.2+35.8+1.5+36.5

+87.6-1.2+88.8-1.0+88.6

—————

UpDownMarket · Nifty Microcap 250Sector · Industrial Products peers, median of 129Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Raymond Ltd reported Q1 FY27 consolidated total income of Rs 628 Cr, up 13% YoY. Revenue from operations rose 15.5% to about Rs 606 Cr. EBITDA grew 14% to Rs 100 Cr with margin at 15.9% vs 15.7% earlier. PAT from continuing operations was Rs 31 Cr vs Rs 21 Cr YoY. Company remains net debt free with Rs 129 Cr cash surplus. Issued 66.57 lakh convertible warrants at Rs 497 each to promoter group entity.

Likely market impact

Steady growth in Aerospace and Defence plus Precision Tech. Net debt-free status and promoter warrant infusion support balance sheet.